{"id":667,"date":"2015-07-30T16:10:42","date_gmt":"2015-07-30T10:40:42","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=667"},"modified":"2025-05-05T17:17:58","modified_gmt":"2025-05-05T11:47:58","slug":"endometrial-cancer-pipeline-insights-2015-a-delveinsights-report","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report","title":{"rendered":"\u201cEndometrial Cancer &#8211; Pipeline Insights, 2015\u201d- A DelveInsight\u2019s Report"},"content":{"rendered":"<p>DelveInsight, the leading market research and consulting company has added a new report \u201c<em><strong>Endometrial Cancer &#8211; Pipeline Insights, 2015\u201d<\/strong><\/em> to its portfolio. With this launch DelveInsight now has <em><strong>700+ Reports on Indication Pipeline Insight<\/strong><\/em>. In addition to this, our research expertise provides our clients with up to date information of market till the date of order.<\/p>\n<p>The Endometrial Cancer &#8211; Pipeline Insights, 2015 report provides client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions.<\/p>\n<p><img decoding=\"async\" class=\" wp-image-668 aligncenter\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/untitled2.jpg?w=300\" alt=\"Untitled\" width=\"410\" height=\"243\" \/><\/p>\n<p><em><strong>Key Highlights of the Report:<\/strong><\/em><\/p>\n<ul>\n<li>The report gives information of <strong>35+ pipeline drugs with 30+ companies<\/strong> actively involved in drug development. There are <strong>7 drugs which are in pre-clinical phase, 10 in phase I, 8 in phase I\/II and 11 in phase II.<\/strong><\/li>\n<li><strong>Aeterna Zentaris<\/strong> is developing a lead product <strong>Zoptarelin doxorubicin<\/strong> which is in <strong>Phase III<\/strong>.<\/li>\n<li>R&amp;D activities and technologies used along with the pipeline molecules in development.<\/li>\n<li>Stages of development of pipeline molecules.<\/li>\n<li>Therapeutic assessments by molecule types, route of <strong>administration, monotherapy and combination products<\/strong>.<\/li>\n<li>Information related to <strong>collaborations, in-licensing and out-licensing deals<\/strong>.<\/li>\n<\/ul>\n<p>DelveInsights, Endometrial Cancer-Pipeline Insights, 2015 report provides Endometrial Cancer Landscape across the globe. Therefore the report on Endometrial Cancer-Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective <strong>counter-strategies to gain competitive advantage<\/strong>.<\/p>\n<p>DelveInsight is offering the Report at a price of <strong>USD 1,250<\/strong> as a single user license, <strong>USD 2,500<\/strong> as a site license and <strong>USD 4,000<\/strong> as a Global\/Enterprise License.<\/p>\n<p>For more information on Pipeline Insight Reports, email at <a href=\"mailto:info@delveInsight.com\">info@delveInsight.com<\/a><\/p>\n<p><strong>About Us<\/strong><\/p>\n<p>DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing <strong>custom research services in coherence with interest area of the clients.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight, the leading market research and consulting company has added a new report \u201cEndometrial Cancer &#8211; Pipeline Insights, 2015\u201d to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date information of market till the date of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[52,67,204,231,323,427,612],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-667","post","type-post","status-publish","format-standard","hentry","category-articles","tag-700-reports-on-indication-pipeline-insight","tag-aeterna-zentaris","tag-delveinsight","tag-endometrial-cancer-pipeline-insights","tag-indication-pipeline-insight-report","tag-oncology","tag-zoptarelin-doxorubicin","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u201cEndometrial Cancer - Pipeline Insights, 2015\u201d- A DelveInsight\u2019s Report<\/title>\n<meta name=\"description\" content=\"DelveInsight, the leading market research and consulting company has added a new report \u201cEndometrial Cancer \u2013 Pipeline Insights, 2015\u201d to its portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u201cEndometrial Cancer - Pipeline Insights, 2015\u201d- A DelveInsight\u2019s Report\" \/>\n<meta property=\"og:description\" content=\"DelveInsight, the leading market research and consulting company has added a new report \u201cEndometrial Cancer \u2013 Pipeline Insights, 2015\u201d to its portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-30T10:40:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T11:47:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/untitled2.jpg?w=300\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u201cEndometrial Cancer - Pipeline Insights, 2015\u201d- A DelveInsight\u2019s Report","description":"DelveInsight, the leading market research and consulting company has added a new report \u201cEndometrial Cancer \u2013 Pipeline Insights, 2015\u201d to its portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report","og_locale":"en_US","og_type":"article","og_title":"\u201cEndometrial Cancer - Pipeline Insights, 2015\u201d- A DelveInsight\u2019s Report","og_description":"DelveInsight, the leading market research and consulting company has added a new report \u201cEndometrial Cancer \u2013 Pipeline Insights, 2015\u201d to its portfolio.","og_url":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-07-30T10:40:42+00:00","article_modified_time":"2025-05-05T11:47:58+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/untitled2.jpg?w=300","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report","url":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report","name":"\u201cEndometrial Cancer - Pipeline Insights, 2015\u201d- A DelveInsight\u2019s Report","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/untitled2.jpg?w=300","datePublished":"2015-07-30T10:40:42+00:00","dateModified":"2025-05-05T11:47:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"DelveInsight, the leading market research and consulting company has added a new report \u201cEndometrial Cancer \u2013 Pipeline Insights, 2015\u201d to its portfolio.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/endometrial-cancer-pipeline-insights-2015-a-delveinsights-report#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/untitled2.jpg?w=300","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/untitled2.jpg?w=300"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">700+ Reports on Indication Pipeline Insight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Aeterna Zentaris<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Endometrial Cancer - Pipeline Insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Indication Pipeline Insight report<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Zoptarelin doxorubicin<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">700+ Reports on Indication Pipeline Insight<\/span>","<span class=\"advgb-post-tax-term\">Aeterna Zentaris<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Endometrial Cancer - Pipeline Insights<\/span>","<span class=\"advgb-post-tax-term\">Indication Pipeline Insight report<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Zoptarelin doxorubicin<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Jul 30, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Jul 30, 2015 4:10 pm","modified":"Updated on May 5, 2025 5:17 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=667"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/667\/revisions"}],"predecessor-version":[{"id":31668,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/667\/revisions\/31668"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=667"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=667"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}